ALS Phase 3 Study TRO19622 Report for Patients Like You

Filter by:

All
Start typing to see suggestions

patients

Home > Community Treatment Reports and Side Effects > ALS Phase 3 Study TRO19622 Treatment Report

You appear to have JavaScript disabled in your browser. PatientsLikeMe relies on JavaScript and Cookies to deliver the best possible experience to you. How do I enable JavaScript?

What is ALS Phase 3 Study TRO19622?

NCT01285583 is an open-label safety extension study of TRO19622 in Amyotrophic Lateral Sclerosis (ALS) patients treated with riluzole. The drug TRO19622 is also known as olesoxime. Other study names are TRO19622 CL E Q 1425-1.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose	# of patients	# of patients with evaluations Efficacy
Participate in clinical trial	3	2
Phase II/III Double-Blind test of TRO19622 in ALS patients treated with Riluzole. http://clinicaltrials.gov/ct2/show/NCT00868166	2	1
2 capsules a day during lunch, placebo or TRO19622	1	0

See all 3 patients currently using ALS Phase 3 Study TRO19622

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe	0
Moderate	0
Mild	0
None	3

Reported Schedules

	2 other daily	2 intl units daily
	1	2

Reported Stop Reasons

Why Patients Stopped Using ALS Phase 3 Study TRO19622 (multiple reasons could be selected)
Reason	# Patients	Percentage of patients
Did not seem to work	1
Other	1

See all 2 patients who’ve stopped using ALS Phase 3 Study TRO19622

Reported Duration See details about how long patients take this treatment ▼ Reported Duration Hide details ▲

Currently Using ALS Phase 3 Study TRO19622

A bar graph

0-1 month	1-3 months	3-6 months	6 months-1year	1-2 years	2 years or more
0	0	0	0	0	2

Stopped Using ALS Phase 3 Study TRO19622

A bar graph

0-1 month	1-3 months	3-6 months	6 months-1year	1-2 years	2 years or more
0	0	0	0	1	1

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of ALS Phase 3 Study TRO19622

Always	3	100%
Usually	0	0%
Sometimes	0	0%
Never	0	0%

Burden

Difficulty being on treatment

Burden of ALS Phase 3 Study TRO19622

Very	0	0%
Somewhat	0	0%
A little	1	33%
Not at all	2	67%

Cost

Paid out of pocket

Cost of ALS Phase 3 Study TRO19622

$200+	0	0%
$100-199	0	0%
$50-99	0	0%
$25-49	0	0%
< $25	1	100%

Patient Evaluations

See all 3 patient evaluations

cinéphile 94

Sex: M

Bulbar: mild

Arms: severe

Chest: moderate

Legs: severe
cinéphile 94

2 other daily

since Dec 14, 2011
Efficacy None for Participate in clinical trial
Side Effects None
Advice/Tips trial results on the 13th of December: no benefits vs placebo See full evaluation